Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFB30132A First-in-Human Study in Healthy Adults
NCT04590430Phase 1Completed
- Sponsor
- HiFiBiO Therapeutics
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing HFB30132A with Placebo (2 arms). Primary endpoints: Treatment emergent serious adverse events, Treatment emergent adverse events of special interest and 8 more. Started Oct 2020; status: completed.
02
Drugs
Enuzovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04590430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04590430.